Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni-15, 40138 Bologna, Italy.
Section of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, 60126 Ancona, Italy.
Int J Mol Sci. 2021 Jun 9;22(12):6237. doi: 10.3390/ijms22126237.
Non-clear cell renal cell carcinomas are a miscellaneous group of tumors that include different histological subtypes, each one characterized by peculiarity in terms of genetic alteration, clinical behavior, prognosis, and treatment response. Because of their low incidence and poor enrollment in clinical trials, alongside their heterogeneity, additional efforts are required to better unveil the pathogenetic mechanisms and, consequently, to improve the treatment algorithm. Nowadays, tyrosine kinase inhibitors, mTOR and MET inhibitors, and even cisplatin-based chemotherapy and immunotherapy are potential weapons that are still under evaluation in this setting. Various biomarkers have been evaluated for detecting progression and monitoring renal cell carcinoma, but more studies are necessary to improve this field. In this review, we provide an overview on the molecular characteristics of this group of tumors and the recently published trials, giving an insight into what might become the future therapeutic standard in this complex world of non-clear cell kidney cancers.
非透明细胞肾细胞癌是一组混杂的肿瘤,包括不同的组织学亚型,每种亚型在遗传改变、临床行为、预后和治疗反应方面都有其独特的特征。由于其发病率低,临床试验入组率低,以及异质性,需要进一步努力以更好地揭示发病机制,从而改善治疗方案。如今,酪氨酸激酶抑制剂、mTOR 和 MET 抑制剂,甚至顺铂为基础的化疗和免疫治疗,都是在这种情况下仍在评估的潜在武器。已经评估了各种生物标志物来检测肾细胞癌的进展和监测,但需要更多的研究来改善这一领域。在这篇综述中,我们概述了这组肿瘤的分子特征和最近发表的试验,深入了解可能成为这个复杂的非透明细胞肾癌治疗领域的未来治疗标准。